Novartis Meningococcal B Recombinant Vaccine
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Novartis Meningococcal B Recombinant Vaccine, covering 2014-10-31 to 2016-01-20. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years [Phase 3]